GlassScriptPhysician profile
Larry D Mckenzie
NPI 1003875212
$4,394.88
in general payments reported to CMS, 2019-2025
48 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $527 · 2021: $496 · 2022: $893 · 2023: $873 · 2024: $489 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $532.26 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Collegium Pharmaceutical, INC. | $524.09 | 2021-2025 | Belbuca, Belbuca, Xtampza |
| Averitas Pharma INC. | $380.31 | 2023-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.21 | 2021-2025 | Relistor |
| Astrazeneca Pharmaceuticals LP | $253.00 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $188.26 | 2019-2023 | Belsomra |
| Novartis Pharmaceuticals Corporation | $168.68 | 2019-2020 | |
| Grt US Holding, INC. | $168.45 | 2021-2022 | |
| Abbvie INC. | $163.17 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $151.52 | 2022-2024 | Ztlido |
| Bayer Healthcare Pharmaceuticals INC. | $145.81 | 2019-2020 | |
| Seagen INC. | $102.04 | 2019-2021 | |
| Lilly USA, LLC | $89.13 | 2019-2020 | |
| Celgene Corporation | $81.86 | 2019 | |
| Genentech USA, INC. | $75.11 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.